NCT04952649 is a clinical trial in Pacemaker Dependence, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT04952649?

NCT04952649 is sponsored by Shanghai Zhongshan Hospital.

What condition does NCT04952649 study?

NCT04952649 studies Pacemaker Dependence.

Is NCT04952649 still recruiting?

NCT04952649 is currently status unknown. Last updated 15 July 2021.

Last reviewed 2021-07-15 · How we verify

NCT04952649

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Ability of Peripheral Perfusion Index To Detect Changes of Hemodynamics in Patients With Pacemaker

Status unknown Last updated 15 July 2021

What this trial tests

trial in Pacemaker Dependence in 50 participants. Status unknown.

Timeline

7 July 2021

Primary endpoint
1 December 2022

30 December 2022

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	7 July 2021
Primary completion	1 December 2022
Estimated completion	30 December 2022
Sites	1 location across China

Conditions studied

Pacemaker Dependence — all drugs for Pacemaker Dependence →

Sponsor

Shanghai Zhongshan Hospital

Who can join

18 and older, any sex, with Pacemaker Dependence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pacemakers are widely used in postcardiotomy patients to avoid severe arrhythmia. The peripheral perfusion index (PI) has been considered as an effective parameter evaluating the circulation. In this study, investigators aim to avaluate the ability of peripheral perfusion index to detect changes of hemodynamics in postcardiotomy patients with pacemakers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04952649 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 15 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04952649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing